Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898723 | 0.96 | NR3C2 (0.36) | NR3C2MAPK14L3MBTL1PDE7AGPR139 | |
| SCHEMBL898935 | 0.89 | NR3C2 (0.36) | NR3C2MAPK14HSD11B1L3MBTL1PDE7A | |
| SCHEMBL899352 | 0.89 | NR3C2 (0.33) | NR3C2 | |
| SCHEMBL899040 | 0.85 | NR3C2 (0.32) | NR3C2 | |
| SCHEMBL898917 | 0.85 | NR3C2 (0.31) | NR3C2 | |
| SCHEMBL898920 | 0.84 | NR3C2 (0.37) | NR3C2MAPK14HSD11B1L3MBTL1PDE7A | |
| SCHEMBL898910 | 0.84 | GLA (0.35) | NR3C2MAPK14PDE2APDE10A | |
| SCHEMBL14990208 | 0.83 | MDM2 (0.32) | NR3C2MDM2 | |
| SCHEMBL898925 | 0.83 | NR3C2 (0.34) | NR3C2MAPK14MDM2 | |
| SCHEMBL898064 | 0.83 | MAPK14 (0.33) | NR3C2MAPK14PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | claimed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | claimed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | NR3C2 2193/4885MAPK14 3555/4885HSD11B1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.